Kaur et al., 2011 - Google Patents

Modification of mouse A2M B (620–792) and A2M N (168–230) by malondialdehyde and acetaldehyde attenuates the proteinase and TGF-β1 binding ability of A2MB

Kaur et al., 2011

View HTML
Document ID
11848101280096502836
Author
Kaur I
Katyal A
Publication year
Publication venue
FEBS letters

External Links

Snippet

Acetaldehyde and malondialdehyde react covalently with cellular proteins forming protein- malondialdehyde–acetaldehyde adducts thus modulating their biochemical functions. Alpha- 2 macroglobulin, an acute phase protein produced by liver binds to cytokines, growth factors …
Continue reading at www.sciencedirect.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Similar Documents

Publication Publication Date Title
d'Ortho et al. MT1-MMP on the cell surface causes focal degradation of gelatin films
Taylor et al. Enhanced potency of human Sonic hedgehog by hydrophobic modification
Nguyen et al. A 16-residue peptide fragment of macrophage migration inhibitory factor, MIF-(50–65), exhibits redox activity and has MIF-like biological functions
Langerholc et al. Inhibitory properties of cystatin F and its localization in U937 promonocyte cells
JP6170940B2 (en) Single domain antibodies as inhibitors of PCSK9
Wartmann et al. Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice
JP7110124B2 (en) Compositions and methods for treating cardiovascular disease
Knudsen et al. Binding of plasminogen to extracellular matrix.
Tang et al. Leptin enhances the effect of transforming growth factor β in increasing type I collagen formation
Baglia et al. A Binding Site for Thrombin in the Apple 1 Domain of Factor XI (∗)
Church et al. A novel approach to the design of inhibitors of human secreted phospholipase A2 based on native peptide inhibition
Bekendam et al. Inhibition of protein disulfide isomerase in thrombosis
Hartland et al. Active matrix metalloproteinase‐2 promotes apoptosis of hepatic stellate cells via the cleavage of cellular N‐cadherin
Chu et al. Plasmin, Substilisin-like Endoproteases, Tissue Plasminogen Activator, and Urokinase Plasminogen Activator Are Involved in Activation of Latent TGF-β1in Human Seminal Plasma
Huang et al. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity
Murray et al. Modulating caspase activity: beyond the active site
Li et al. Retigabine ameliorates acute stress-induced impairment of spatial memory retrieval through regulating USP2 signaling pathways in hippocampal CA1 area
Kaur et al. Modification of mouse A2M B (620–792) and A2M N (168–230) by malondialdehyde and acetaldehyde attenuates the proteinase and TGF-β1 binding ability of A2MB
Chamani et al. Engineering of a disulfide loop instead of a Zn binding loop restores the anti-proliferative, anti-angiogenic and anti-tumor activities of the N-terminal fragment of endostatin: Mechanistic and therapeutic insights
Poliakov et al. Structure–activity relationships for the selectivity of hepatitis C virus NS3 protease inhibitors
Love et al. Developing an antibody–drug conjugate approach to selective inhibition of an extracellular protein
Yamauchi et al. Redox status of serum apolipoprotein E and its impact on HDL cholesterol levels
Roussel et al. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator
Glasgow et al. A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the regulation of the inflammatory response in the lung
Bianchi et al. Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors